Early Detection, Early Intervention

Cancer is the second leading cause of death worldwide. An estimated 9.6 million people died or cancer in 2018, accounting for one sixth of all deaths. Lung cancer and liver cancer are the most common types of cancer in men, while breast cancer is the most common type of cancer in women.

Cancer refers to malignant tumors caused by the accumulation of genetic mutations, and is becoming a controllable chronic disease. After surgical resection of early malignant tumors, patients have a higher chance of survival and better life quality. However, 50%-80% of malignant tumor patients are diagnosed at the middle or late stages, which leads to low survival rates, high treatment costs and painful medical

treatment. Therefore, the development process of tumors from the molecular level to the cellular level, and then to the tissue level provides a window period for cancer screening and early detection. The World Health Organization (WHO) advocates early cancer screening to detect and actively intervene before or in the early stage of cancer. In this way, the 5-year survival rate of patients will exceed 80%, and can even reach 100% for some cancers.

Vangenes Cancer Screening and Early Detection Technology

Vangenes has developed a simpler, safer and more effective method for early cancer screening by detecting methylation signals of tumor-related genes in peripheral blood. Our proprietary EM-seq technology can accurately detect the methylation status of tumor-related cell-free DNA. Combined with high-throughput sequencing and deep learning models, our technology can accurately distinguish cancer patients from healthy people, providing strong support for early tumor detection.

Our Advantages

  • Only 1 tube of

    blood sample is

    needed to check

    3 types of cancers

  • Proprietary technology  

    ensures highly efficient

    and effective detection

  • EM-seq method

    greatly enhances

    reliability and

    repeatability

  • Specificity 90%+

    Sensivity 85%+

    in detecting the

    3 types of cancers

Applicable Groups

  • Early Screening for Liver Cancer

    ■ People infected with  hepatitis B/C

    ■ People who drink excessively

    ■ Patients with hepatitis and cirrhosis

    ■ People who eat foods containing aflatoxin

    ■ People with a family history of liver cancer

  • Early Screening for Lung Cancer

    ■ People who smoke

    ■ People exposed to secondhandsmoke/cooking fumes

    ■ People exposed to oc  cupational carcinogens

    ■ People with a history  of chronic lung disease

    ■ People with a family  history of lung cancer

  • Early Screening for Breast Cancer

    ■ People who have genetic tendency breast cancer

    ■ Patients with breast  ductal/lobular atypical  hyperplasia or lobular  carcinoma in situ;

    ■ People who have re ceived breast radiotherapy